Yannick MD - Acticor Biotech GM Officer
| ALACT Stock | EUR 0.27 0.01 3.57% |
Insider
Yannick MD is GM Officer of Acticor Biotech SAS
| Phone | 33 9 70 46 86 40 |
| Web | https://acticor-biotech.com |
Acticor Biotech Management Efficiency
The company has return on total asset (ROA) of (0.6851) % which means that it has lost $0.6851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.3291) %, meaning that it generated substantial loss on money invested by shareholders. Acticor Biotech's management efficiency ratios could be used to measure how well Acticor Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Claire GallRobinson | SCOR SE | 48 | |
| Phalla Gervais | Coface SA | 55 | |
| Brona Magee | SCOR SE | 47 | |
| Laurent Rousseau | SCOR SE | 44 | |
| JeanPaul ConoscenteJacopin | SCOR SE | 58 | |
| Marc Philippe | SCOR SE | 54 | |
| Frederic Bourgeois | Coface SA | N/A | |
| Nicolas Papadopoulo | Coface SA | 57 | |
| Marie Allavena | Coface SA | 58 | |
| Nathalie Bricker | Coface SA | 50 | |
| Vronique BdagueHamilius | Nexity | 59 | |
| Romain Launay | SCOR SE | 43 | |
| Ian Kelly | SCOR SE | 56 | |
| Janice Englesbe | Coface SA | 51 | |
| Franck Marzilli | Coface SA | N/A | |
| Bruno Krief | Rubis SCA | N/A | |
| Franois Varenne | SCOR SE | 57 | |
| Daniel Karyotis | Coface SA | 58 | |
| Isabelle Laforgue | Coface SA | 39 | |
| Frederic Augier | Nexity | N/A | |
| Nathalie Lomon | Coface SA | 48 | |
Management Performance
| Return On Equity | -3.33 | |||
| Return On Asset | -0.69 |
Acticor Biotech SAS Leadership Team
Elected by the shareholders, the Acticor Biotech's board of directors comprises two types of representatives: Acticor Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acticor. The board's role is to monitor Acticor Biotech's management team and ensure that shareholders' interests are well served. Acticor Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acticor Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilles MD, CEO Founder | ||
| Patrice Coffe, Administrative and Financial Director, Member of the Board | ||
| Eric Cohen, Chief Officer | ||
| Julien Parrou, Chairman of the Board, Chief Executive Officer | ||
| Hugues Duboscq, Director - Permanent Representative of Saint-Florentin Participations | ||
| Martine MD, Scientific Founder | ||
| Victoria PharmD, Head Assurance | ||
| Jerome Leleu, Director | ||
| PharmD Billiald, Scientific Founder | ||
| Frederic Bartoli, Director - Representative of Chorus | ||
| JeanLuc Riviere, Director - Representative of IXO PRIVATE EQUITY | ||
| Sophie LebelBinay, Chief GM | ||
| Laurie Jullien, Head Affairs | ||
| Aymeric Humblot, Head Admin | ||
| Yannick MD, GM Officer | ||
| Kristell Lebozec, Head Devel |
Acticor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acticor Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.33 | |||
| Return On Asset | -0.69 | |||
| Current Valuation | 76.26 M | |||
| Shares Outstanding | 10.52 M | |||
| Price To Earning | 35.47 X | |||
| Price To Book | 18.24 X | |||
| Price To Sales | 5.71 X | |||
| Gross Profit | 320.18 K | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.61 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.